Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom

Currently, the 13-valent pneumococcal conjugate vaccine (PCV13) is administered under a 1+1 (1 primary dose) pediatric schedule in the United Kingdom (UK). Higher-valency PCVs, 15-valent PCV (PCV15), or 20-valent PCV (PCV20) might be considered to expand serotype coverage. We evaluated the cost-effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Michele, Lucas, Aaron, Mendes, Diana, Vyse, Andrew, Mikudina, Boglarka, Czudek, Carole, Ellsbury, Gillian Frances, Perdrizet, Johnna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386052/
https://www.ncbi.nlm.nih.gov/pubmed/37514984
http://dx.doi.org/10.3390/vaccines11071168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386052/
https://www.ncbi.nlm.nih.gov/pubmed/37514984
http://dx.doi.org/10.3390/vaccines11071168

Ejemplares similares